QUICK SPARK: Martin Shkreli Shorts Hims & Hers Stock, Says 'Peptides Are Fake Medicine'
Martin Shkreli is taking aim at Hims & Hers Health (NYSE:HIMS), saying he is short the stock and blasting the company’s peptide products as illegitimate medicine
Shkreli, known as Pharma Bro, posted on X that he is "shorted $HIMS" and calling its peptides "fake medicine," adding that "we have come far in the last 70 years of medicine, let’s not go backwards."
FDA’s Stance on Peptides
- Hims & Hers Health’s peptide narrative faces challenges as the FDA recommended against adding seven peptides to the 503A Bulk List. This recommendation, noted by BofA Securities analyst Allen Lutz in a July 1 report, could narrow the legal pathway for peptide compounding.
- The FDA’s briefing materials suggest that the Pharmacy Compounding Advisory Committee (PCAC) has a difficult task ahead in attempting to shift the FDA’s stance on these peptides.
Stock Movement and Advisory Vote
- The stock surged on Thursday after an FDA advisory committee voted to add the BPC-157 peptide to the allowed pharmacy compounding list. This decision, reported on Thursday, has driven positive sentiment in the market.
- Despite the FDA’s initial recommendations, the advisory panel’s vote indicates potential for Hims & Hers to expand its peptide offerings under the 503A framework.
Technical Analysis
Hims & Hers Health trades at $32.79, with a market cap of $7.33 billion. The stock is currently trading +8.43% above its 50-day simple moving average of $30.24 and +5.13% above its 200-day SMA of $31.19.
The stock’s largest one-day move was a 40.79% increase on March 9, 2026, and it has experienced a death cross since Dec. 8, 2025, when the 50-day SMA fell below the 200-day SMA.
Read also
- Hims & Hers Stock Surges as Analysts Lift Price Targets
- Hims & Hers Stock Jumps After Barclays Raises Price Target
- Hims & Hers Stock Is Climbing Tuesday: What Investors Need To Know
Image: Shutterstock